drugset
drugset / Trial / NCT07137481

Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

NCT07137481 ↗

Phase 2 Not yet recruiting 70 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

To determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.

Timeline

Start
2027-02-28
Primary completion
2030-07-31
Completion
2032-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject C9/CD5CAR/IL-15 NK cells Cell therapy — Oral
Background Cyclophosphamide Other / unclassified — Intravenous
Background Fludarabine Small molecule — Intravenous
Background Rituximab Monoclonal antibody — Intravenous

Indications

hematopoietic and lymphoid cell neoplasm